Suppr超能文献

中欧地区胱硫醚β-合酶缺乏症:同型胱氨酸尿症等位基因生化筛查与分子遗传学筛查之间的差异

Cystathionine beta-synthase deficiency in Central Europe: discrepancy between biochemical and molecular genetic screening for homocystinuric alleles.

作者信息

Sokolová J, Janosíková B, Terwilliger J D, Freiberger T, Kraus J P, Kozich V

机构信息

Institute of Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

出版信息

Hum Mutat. 2001 Dec;18(6):548-9. doi: 10.1002/humu.1239.

Abstract

Recent reports suggested that homocystinuria due to cystathionine beta-synthase (CBS) deficiency is a more common inborn error of metabolism than originally thought. In this study we compared the prevalence of homocystinuric alleles ascertained by two different approaches. First, the incidence of homocystinuria estimated by selective biochemical screening in the Czech and Slovak Republics was 1:349,000 (95% CI 1:208,000-1:641,000). The two most common pathogenic mutant alleles found subsequently in these patients, IVS11-2A>C and c.833T>C, had a calculated population prevalence of 0.00042 (95% CI 0.00031-0.00055) and 0.00018 (95% CI 0.00013-0.00023), respectively. Second, to examine the possible negative detection bias of mildly affected patients we determined the prevalence of these two pathogenic mutations in a sample of 1284 unselected newborns. Indeed, the observed prevalence of the c.833T>C allele (0.00195, 95% CI 0.00063-0.00454) was 11x higher than in the previous group suggesting that many homozygotes for the c.833T>C had not been diagnosed by selective biochemical screening. The IVS11-2A>C allele was not detected among 2,568 newborn CBS alleles. The estimated incidence of homocystinuria of 1:83,000, calculated in a combined model, suggests that selective biochemical screening may ascertain only approximately 25% of all homocystinuric patients. In conclusion, homocystinuria in Central Europe may be sufficiently common to consider sensitive newborn screening programs for this disease.

摘要

最近的报告表明,由于胱硫醚β-合酶(CBS)缺乏引起的同型胱氨酸尿症是一种比原先认为的更为常见的先天性代谢缺陷。在本研究中,我们比较了通过两种不同方法确定的同型胱氨酸尿症等位基因的患病率。首先,通过在捷克共和国和斯洛伐克共和国进行选择性生化筛查估计同型胱氨酸尿症的发病率为1:349,000(95%可信区间1:208,000 - 1:641,000)。随后在这些患者中发现的两个最常见的致病突变等位基因,IVS11 - 2A>C和c.833T>C,计算得出的群体患病率分别为0.00042(95%可信区间0.00031 - 0.00055)和0.00018(95%可信区间0.00013 - 0.00023)。其次,为了检查症状较轻患者可能存在的漏检偏倚,我们在1284名未经过筛选的新生儿样本中确定了这两个致病突变的患病率。实际上,观察到的c.833T>C等位基因的患病率(0.00195,95%可信区间0.00063 - 0.00454)比前一组高11倍,这表明许多c.833T>C纯合子未通过选择性生化筛查被诊断出来。在2568个新生儿CBS等位基因中未检测到IVS11 - 2A>C等位基因。通过综合模型计算得出的同型胱氨酸尿症估计发病率为1:83,000,这表明选择性生化筛查可能仅能确诊约25%的所有同型胱氨酸尿症患者。总之,在中欧,同型胱氨酸尿症可能足够常见,值得考虑针对该疾病开展敏感的新生儿筛查项目。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验